Performance Summary Against Maryland and National Benchmarks
Report Year
Report Year 2020
The information provides a summary of clinical performance measures and indicators, as well as an account of how many of the Maryland health benefit plans had quality and performance scores equivalent to or better than the Maryland average, performance scores at or better than the National average, and performance scores at or better than the top ten percent nationally. Notes specific to each measure, where appropriate, are provided.
The information provides a summary of clinical performance measures and indicators, as well as an account of how many of the Maryland health benefit plans had quality and performance scores equivalent to or better than the Maryland average, performance scores at or better than the National average, and performance scores at or better than the top ten percent nationally. Notes specific to each measure, where appropriate, are provided.
Excellent Performance Areas
Maryland’s health benefit plans are maintaining a track record of good performance across many of the measures and indicators being evaluated. When considering all measures, several stand out for high performance and corresponding star assignment.
1. In the category Primary Care and Wellness for Children and Adolescents, the results show that health benefit plans are maintaining a focus on services to children and adolescents. For HMO and PPO products, children received a visit to primary care providers within the first 15 months of life. The results also show that the majority of plans ensure children and adolescents receive the required immunizations by their designated ages. For children on antipsychotics, the majority had the required metabolic testing for blood glucose and cholesterol. Additionally, concurrent antipsychotics were used and managed well in both children and adolescents. For this year, there was also an increase in appropriate cervical cancer screening for adolescents.
Childhood Immunization Status (Combo 10)
Immunizations for Adolescents (Combo 1)
Well-Child Visits in the First 15 Months of Life
Use of Multiple Concurrent Antipsychotics in Children and Adolescents
Metabolic Monitoring for Children and Adolescents on Antipsychotics
2. In the category Respiratory Conditions, the results show that health benefit plans are properly managing patients with asthma.
Medication Management for People with Asthma
Asthma Medication Ratio
3. In the category Primary Care for Adults – Respiratory Conditions and Cardiovascular Conditions, the results show that statin therapy is being appropriately provided to diabetics, plus those patients with a history of cardiovascular disease. Additionally, recommended long term medication for asthma was provided for adults in various age groups.
Statin Therapy for Patients with Diabetes (80% adherence)
4. In the category of Behavioral Health, the results show that health benefit plans are ensuring members are receiving appropriate treatment for alcohol and/or drug dependence and that anyone admitted for depression is provided the appropriate medication coverage.
Initiation of Alcohol and Other Drug Dependence Treatment
Antidepressant Medication Management (Continuation Phase Treatment of 180 days)
1. In the category Primary Care and Wellness for Children and Adolescents, the results show that health benefit plans are maintaining a focus on services to children and adolescents. For HMO and PPO products, children received a visit to primary care providers within the first 15 months of life. The results also show that the majority of plans ensure children and adolescents receive the required immunizations by their designated ages. For children on antipsychotics, the majority had the required metabolic testing for blood glucose and cholesterol. Additionally, concurrent antipsychotics were used and managed well in both children and adolescents. For this year, there was also an increase in appropriate cervical cancer screening for adolescents.
Childhood Immunization Status (Combo 10)
Immunizations for Adolescents (Combo 1)
Well-Child Visits in the First 15 Months of Life
Use of Multiple Concurrent Antipsychotics in Children and Adolescents
Metabolic Monitoring for Children and Adolescents on Antipsychotics
2. In the category Respiratory Conditions, the results show that health benefit plans are properly managing patients with asthma.
Medication Management for People with Asthma
Asthma Medication Ratio
3. In the category Primary Care for Adults – Respiratory Conditions and Cardiovascular Conditions, the results show that statin therapy is being appropriately provided to diabetics, plus those patients with a history of cardiovascular disease. Additionally, recommended long term medication for asthma was provided for adults in various age groups.
Statin Therapy for Patients with Diabetes (80% adherence)
4. In the category of Behavioral Health, the results show that health benefit plans are ensuring members are receiving appropriate treatment for alcohol and/or drug dependence and that anyone admitted for depression is provided the appropriate medication coverage.
Initiation of Alcohol and Other Drug Dependence Treatment
Antidepressant Medication Management (Continuation Phase Treatment of 180 days)
Areas That Need Improvement
Overall, the health benefit plans continue to perform well when compared to the national average. In fact, rates improved in all areas in comparison to prior years of reporting and areas needing improvement decreased. However, there are several where overall performance is less than desired and the corresponding star assignment is low.
1. In the category Primary Care and Wellness for Children and Adolescents, the results show that health benefit plans are not providing children with access to primary care visits.
Children’s Access to Primary Care (All age groups
2. In the category Primary Care for Adults – General Health, the results show that adults age 19-74 are not gaining the appropriate access to primary care providers and that adults with opioid use are at very high rates.
Adult’s Access to Primary Care
3. In the category Primary Care for Adults – Respiratory Conditions, the results show that adults were being given antibiotics for bronchitis, which is not recommended within the first few days after diagnosis. Additionally, there has not been the use of appropriate testing to diagnose COPD in patients.
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis
Use of Spirometry Testing in the Assessment and Diagnosis of COPD
1. In the category Primary Care and Wellness for Children and Adolescents, the results show that health benefit plans are not providing children with access to primary care visits.
Children’s Access to Primary Care (All age groups
2. In the category Primary Care for Adults – General Health, the results show that adults age 19-74 are not gaining the appropriate access to primary care providers and that adults with opioid use are at very high rates.
Adult’s Access to Primary Care
3. In the category Primary Care for Adults – Respiratory Conditions, the results show that adults were being given antibiotics for bronchitis, which is not recommended within the first few days after diagnosis. Additionally, there has not been the use of appropriate testing to diagnose COPD in patients.
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis
Use of Spirometry Testing in the Assessment and Diagnosis of COPD
Maryland Average Benchmark (MAB)
Maryland Average Benchmark (MAB): The Maryland Average Benchmark is an average of the rates as reported to NCQA for the health benefit plans in this report. The average is calculated for six HMOs and authorized HMO combinations such as HMO/POS plan combinations and four PPOs and authorized PPO combinations such as PPO/EPO plan combinations. If a health benefit plan reported: NA, indicating Not Applicable due to an insufficient eligible population (e.g., <30 members, or <100 survey respondents) to calculate a rate; NB, indicating No Benefit offered by the health benefit plan; UN, measure was unaudited: BR, indicating the performance score was bias and not reported; then the NA, NB, BR, and UN performance results were not included in the calculation of the Maryland Average Benchmark.
National Average Benchmark (NAB)
National Average Benchmark (NAB): The National Average Benchmark is an average of the rates as reported to NCQA for all of the health benefit plans across the United States and its territories. A mean value of each reported rate is taken from NCQA’s HEDIS® Audit Means, Percentiles and Ratios – Commercial HMO/POS and Commercial PPO Plans, which is released to the public each year. The NCQA data set gives prior year rates for each measure displayed as the mean rate and the rate at the 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentiles. NCQA averages the rates of all organizations submitting HEDIS® performance results gathered through the administrative, supplemental or hybrid methods. Therefore, the method for calculating the NAB is the same as that used for calculating the MAB, but on a larger scale. The star assignment is based on plan performance in relationship to the percentiles. The percentiles used here are based on quality and performance reported in 2019.
National Top Performers (NTP) Benchmark
National Top Performers (NTP) Benchmark: The National Top Performers benchmark represents one of the highest performance levels that can be achieved by health benefit plans. When all of the performance scores reported to NCQA for a particular measure are compared, the NTP marks the bar where eighty-nine percent of the health benefit plans had a lower score and ten percent had a higher score. The NTP is different from the MAB and NAB, which are averages calculated from all reported performance scores. The NTP represents a specific placeholder of all scores reported when they are sorted from lower to higher performance score. It serves as a clear indication and comparison of the health benefit plan’s performance in comparison to peers reporting the same product without regard to size of health benefit plan or geographic service area. A health benefit plan is to be applauded if they meet or exceed the NTP benchmark.
Health Plans Achieving NTP Standards
Please Select A Health Plan Below to see which measures met the NTP Standard.
Aetna HMO
Number of measures achieving National Top Performance levels: 16
Persistence of Beta Blocker Treatment after Heart Attack
Statin Therapy for Patients with Cardiovascular Disease
• Statin Adherence 80% - 21-75 years (Male)
Statin Therapy for Patients with Cardiovascular Disease
• Statin Adherence 80% - Total
Statin Therapy for Patients with Diabetes
• Statin Adherence 80% - Total
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers and Pharmacies
Risk of Continued Opioid Use
• 18-64, 31+ days
• 65+, 31+ days
• Total, 31+ days
Pharmacotherapy Management of COPD Exacerbation (Bronchodilator)
Medication Management for People with Asthma (Totals)
• Med Compliance 75% 5-11 Years
• Med Compliance 75% 12-18 Years
• Med Compliance 75% 51-64 Years
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
Persistence of Beta Blocker Treatment after Heart Attack
Statin Therapy for Patients with Cardiovascular Disease
• Statin Adherence 80% - 21-75 years (Male)
Statin Therapy for Patients with Cardiovascular Disease
• Statin Adherence 80% - Total
Statin Therapy for Patients with Diabetes
• Statin Adherence 80% - Total
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers and Pharmacies
Risk of Continued Opioid Use
• 18-64, 31+ days
• 65+, 31+ days
• Total, 31+ days
Pharmacotherapy Management of COPD Exacerbation (Bronchodilator)
Medication Management for People with Asthma (Totals)
• Med Compliance 75% 5-11 Years
• Med Compliance 75% 12-18 Years
• Med Compliance 75% 51-64 Years
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
CareFirst HMO
Number of measures achieving National Top Performance levels: 17
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics
• 12-17 years
• Total
Follow-Up after Emergency Department Visit for Alcohol and Other Drug Dependence
• 7 Days - 13-17
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers and Pharmacies
Risk of Continued Opioid Use
• 18-64, 15+ days
• 65+, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
• Total, 31+ days
Medication Management for People with Asthma (75%)
• 19-50 years of age
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
• 6 visits
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics
• 12-17 years
• Total
Follow-Up after Emergency Department Visit for Alcohol and Other Drug Dependence
• 7 Days - 13-17
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers and Pharmacies
Risk of Continued Opioid Use
• 18-64, 15+ days
• 65+, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
• Total, 31+ days
Medication Management for People with Asthma (75%)
• 19-50 years of age
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
• 6 visits
Kaiser Permanente HMO
Number of measures achieving National Top Performance levels: 80
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment
Use of Multiple Concurrent Antipsychotics in Children and Adolescents
• 6-11 Years
• 12-17 Years
• Total
Use of Imaging Studies for Low Back Pain
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis
Non-Recommended Cervical Cancer Screening in Adolescent Females
Prenatal and Postpartum Care
• Timeliness of Prenatal Care
• Postpartum Care
Follow-Up Care for Children Prescribed ADHD Medication
• Initiation
• Continuation
Metabolic Monitoring for Children and Adolescents on Antipsychotics
• 6-11 Years
• 12-17 Years
• Total
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics
• 12-17 Years
• Total
Follow-Up After Hospitalization for Mental Illness
• 7 Day Total
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence
• 7 Day Total
• 30 Day 18+
• 30 Day Total
Controlling High Blood Pressure
Persistence of Beta Blocker Treatment after Heart Attack
Statin Therapy for Patients with Cardiovascular Disease
• Received Statin Therapy: All age groups and Total
Comprehensive Diabetes Care
• HbA1c testing and levels
• Poor HbA1c Control (>9.0%)
• HbA1c Control (<8.0%)
• Medical attention for nephropathy
• Eye Exam
• BP Control (<140/90)
Statin Therapy for Patients with Diabetes
• Received Statin Therapy
Annual Monitoring for Patients on Persistent Medications
• ACE inhibitors or ARBs
• Diuretics
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis
Adult BMI Assessment
Weight Assessment & Counseling for Nutrition & Physical Activity for Children/Adolescents
• BMI Percentile - Total
• Counseling for Nutrition - Total
• Counseling for Physical Activity - Total
Immunizations for Adolescents
• Combo 1
Breast Cancer Screening
Cervical Cancer Screening
Colorectal Cancer Screening
Chlamydia Screening in Women
• Total
Pharmacotherapy Management of COPD Exacerbation
• Systemic corticosteroid
• Bronchodilator
Appropriate Treatment for Children With URI
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
Childhood Immunization Status
• Combo 10
Asthma Medication Ratio
• 12-18 Years
• 19-50 Years
• 51-64 Years
Well Child Visits Age 3, 4, 5, 6 Years of Age
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Prescribers
Risk of Continued Opioid Use
• 18-64, 15+ days
• 65+, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
• Total, 31+ days
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment
Use of Multiple Concurrent Antipsychotics in Children and Adolescents
• 6-11 Years
• 12-17 Years
• Total
Use of Imaging Studies for Low Back Pain
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis
Non-Recommended Cervical Cancer Screening in Adolescent Females
Prenatal and Postpartum Care
• Timeliness of Prenatal Care
• Postpartum Care
Follow-Up Care for Children Prescribed ADHD Medication
• Initiation
• Continuation
Metabolic Monitoring for Children and Adolescents on Antipsychotics
• 6-11 Years
• 12-17 Years
• Total
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics
• 12-17 Years
• Total
Follow-Up After Hospitalization for Mental Illness
• 7 Day Total
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence
• 7 Day Total
• 30 Day 18+
• 30 Day Total
Controlling High Blood Pressure
Persistence of Beta Blocker Treatment after Heart Attack
Statin Therapy for Patients with Cardiovascular Disease
• Received Statin Therapy: All age groups and Total
Comprehensive Diabetes Care
• HbA1c testing and levels
• Poor HbA1c Control (>9.0%)
• HbA1c Control (<8.0%)
• Medical attention for nephropathy
• Eye Exam
• BP Control (<140/90)
Statin Therapy for Patients with Diabetes
• Received Statin Therapy
Annual Monitoring for Patients on Persistent Medications
• ACE inhibitors or ARBs
• Diuretics
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis
Adult BMI Assessment
Weight Assessment & Counseling for Nutrition & Physical Activity for Children/Adolescents
• BMI Percentile - Total
• Counseling for Nutrition - Total
• Counseling for Physical Activity - Total
Immunizations for Adolescents
• Combo 1
Breast Cancer Screening
Cervical Cancer Screening
Colorectal Cancer Screening
Chlamydia Screening in Women
• Total
Pharmacotherapy Management of COPD Exacerbation
• Systemic corticosteroid
• Bronchodilator
Appropriate Treatment for Children With URI
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
Childhood Immunization Status
• Combo 10
Asthma Medication Ratio
• 12-18 Years
• 19-50 Years
• 51-64 Years
Well Child Visits Age 3, 4, 5, 6 Years of Age
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Prescribers
Risk of Continued Opioid Use
• 18-64, 15+ days
• 65+, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
• Total, 31+ days
MD IPA HMO
Number of measures achieving National Top Performance levels: 20
Use of Imaging Studies for Low Back Pain
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Prescribers
Risk of Continued Opioid Use
• 18-64, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
• Total, 31+ days
Childhood Immunization Status
• Combo 10
Medication Management for People with Asthma- Med Compliance 75%
• 51-64 Years
Asthma Medication Ratio
• 12-18 Years
• 19-50 Years
Use of Imaging Studies for Low Back Pain
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Prescribers
Risk of Continued Opioid Use
• 18-64, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
• Total, 31+ days
Childhood Immunization Status
• Combo 10
Medication Management for People with Asthma- Med Compliance 75%
• 51-64 Years
Asthma Medication Ratio
• 12-18 Years
• 19-50 Years
OptimumChoice HMO
Number of measures achieving National Top Performance levels: 13
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
Persistence of Beta Blocker Treatment after Heart Attack
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 18-64, 15+ days
• 65+, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
• Total, 31+ days
Asthma Medication Ratio
• 12-18 Years
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
Persistence of Beta Blocker Treatment after Heart Attack
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 18-64, 15+ days
• 65+, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
• Total, 31+ days
Asthma Medication Ratio
• 12-18 Years
UnitedHealthcare HMO
Number of measures achieving National Top Performance levels: 13
Initiation and Engagement of AOD Abuse or Dependence Treatment
• Engagement Alcohol Abuse 18+
• Engagement Alcohol Abuse Total
• Engagement Total 18+
• Engagement Total Tot
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 18-64, 15+ days
• 65+, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
Follow-up Care For Children Prescribed ADHD Medications
• Initiation Phase
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
• 6 visits (inverse ratio)
Initiation and Engagement of AOD Abuse or Dependence Treatment
• Engagement Alcohol Abuse 18+
• Engagement Alcohol Abuse Total
• Engagement Total 18+
• Engagement Total Tot
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 18-64, 15+ days
• 65+, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
Follow-up Care For Children Prescribed ADHD Medications
• Initiation Phase
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
• 6 visits (inverse ratio)
Aetna PPO
Number of measures achieving National Top Performance levels: 15
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 65+, 15+ days
• 18-64, 31+ days
• 65+, 31+ day
• Total, 31+ days
Medication Management for People with Asthma
• Med Compliance 50% -5-11 Years
• Med Compliance 75% -5-11 Years
• Med Compliance 75% -19-50 Years
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics
• 12-17 Years
• Total
Engagement of Alcohol and Other Drug Dependence Treatment - Total
• Engagement within 34 days 13+
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 65+, 15+ days
• 18-64, 31+ days
• 65+, 31+ day
• Total, 31+ days
Medication Management for People with Asthma
• Med Compliance 50% -5-11 Years
• Med Compliance 75% -5-11 Years
• Med Compliance 75% -19-50 Years
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics
• 12-17 Years
• Total
Engagement of Alcohol and Other Drug Dependence Treatment - Total
• Engagement within 34 days 13+
CareFirst PPO
Number of measures achieving National Top Performance levels: 22
Children and Adolescent's Access to Primary Care Providers
• 25 Months-6 Years
Adults' Access to Preventative / Ambulatory Health Services – Total
• 20-44 years
• 45-64 years
Use of Multiple Concurrent Antipsychotics in Children and Adolescents
• 12-17 Years
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics
• 12-17 Years
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 65+, 15+ days
• 18-64, 31+ days
• 65+, 31+ day
• Total, 31+ days
Cervical Cancer Screening
Pharmacotherapy Management of COPD Exacerbation
• Bronchodilator
Asthma Medication Ratio
• 19-50 Years
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
• 6+ visits (inverse ratio)
Children and Adolescent's Access to Primary Care Providers
• 25 Months-6 Years
Adults' Access to Preventative / Ambulatory Health Services – Total
• 20-44 years
• 45-64 years
Use of Multiple Concurrent Antipsychotics in Children and Adolescents
• 12-17 Years
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics
• 12-17 Years
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 65+, 15+ days
• 18-64, 31+ days
• 65+, 31+ day
• Total, 31+ days
Cervical Cancer Screening
Pharmacotherapy Management of COPD Exacerbation
• Bronchodilator
Asthma Medication Ratio
• 19-50 Years
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
• 6+ visits (inverse ratio)
Cigna PPO
Number of measures achieving National Top Performance levels: 16
Follow-up After Hospitalization for Mental Illness
• within 7 days of discharge (18-64 years)
• within 7 days of discharge (Total)
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 18-64, 15+ days
• 65+, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
Immunization for Adolescents
• Combo 1
Pharmacotherapy Management of COPD Exacerbation
• Bronchodilator
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
• 6 visits (inverse ratio)
Follow-up After Hospitalization for Mental Illness
• within 7 days of discharge (18-64 years)
• within 7 days of discharge (Total)
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 18-64, 15+ days
• 65+, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
Immunization for Adolescents
• Combo 1
Pharmacotherapy Management of COPD Exacerbation
• Bronchodilator
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
• 6 visits (inverse ratio)
MAMSI PPO
Number of measures achieving National Top Performance levels: 17
Engagement of Alcohol and Other Drug Dependence Treatment - Total
• Initiation Other drug abuse18+
• Initiation Other drug abuse Tot
Follow-Up after Emergency Department Visit for Alcohol and Other Drug Dependence
• 7 Days - 18+
• 7 Days - Total
• 30 Days - 18+
• 30 Days – Total
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 18-64, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• Total, 31+ days
Chilhood Immunization Status
• Combo 10
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
• 2 visits (inverse ratio)
Engagement of Alcohol and Other Drug Dependence Treatment - Total
• Initiation Other drug abuse18+
• Initiation Other drug abuse Tot
Follow-Up after Emergency Department Visit for Alcohol and Other Drug Dependence
• 7 Days - 18+
• 7 Days - Total
• 30 Days - 18+
• 30 Days – Total
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 18-64, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• Total, 31+ days
Chilhood Immunization Status
• Combo 10
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
• 2 visits (inverse ratio)
UnitedHealthcare PPO
Number of measures achieving National Top Performance levels: 12
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics
• 12-17 Years
• Total
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 18-64, 15+ days
• 65+, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
• Total, 31+ days
Immunizations for Adolescents
• Combo 1
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics
• 12-17 Years
• Total
Use of Opioids at High Dosage
Use of Opioids from Multiple Providers
• Multiple Pharmacies
• Multiple Prescribers
• Multiple Prescribers & Pharmacies
Risk of Continued Opioid Use
• 18-64, 15+ days
• 65+, 15+ days
• Total, 15+ days
• 18-64, 31+ days
• 65+, 31+ days
• Total, 31+ days
Immunizations for Adolescents
• Combo 1
Well-Child Visits in the First 15 Months of Life
• 0 visits (inverse ratio)
